Published in Br J Cancer on August 01, 2006
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther (2011) 1.24
TCF12 protein functions as transcriptional repressor of E-cadherin, and its overexpression is correlated with metastasis of colorectal cancer. J Biol Chem (2011) 1.05
Noninvasive multiparametric imaging of metastasis-permissive microenvironments in a human prostate cancer xenograft. Cancer Res (2009) 0.90
The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol (2012) 0.89
Human prostatic acid phosphatase: structure, function and regulation. Int J Mol Sci (2013) 0.85
A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) (2012) 0.78
Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists. Ther Adv Med Oncol (2011) 0.77
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev (2004) 7.89
Systems biology and new technologies enable predictive and preventative medicine. Science (2004) 7.59
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89
The application of mass spectrometry to membrane proteomics. Nat Biotechnol (2003) 2.61
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res (2005) 2.11
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst (2004) 1.99
Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res (2004) 1.83
Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem (1999) 1.65
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer (2005) 1.59
ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res (2000) 1.51
Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res (2001) 1.34
Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev (2005) 1.33
Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res (2005) 1.15
Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol (2004) 1.15
Phosphorylation of the RNA-dependent protein kinase regulates its RNA-binding activity. Nucleic Acids Res (2001) 1.05
Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology (2003) 0.97
Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer (2002) 0.95
Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett (1999) 0.87
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
Effect of yoga therapy on facial emotion recognition deficits, symptoms and functioning in patients with schizophrenia. Acta Psychiatr Scand (2010) 2.93
Role of CED-4 in the activation of CED-3. Nature (1997) 2.76
ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem (1996) 2.20
Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol (2007) 2.17
ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem (1996) 2.12
A role for FADD in T cell activation and development. Immunity (1998) 2.09
The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem (1996) 1.84
Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem (1997) 1.56
Anxiolytic effects of a yoga program in early breast cancer patients undergoing conventional treatment: a randomized controlled trial. Complement Ther Med (2008) 1.44
Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res (2001) 1.39
CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene (1996) 1.33
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene (2011) 1.32
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene (2010) 1.29
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene (2006) 1.25
In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci U S A (1993) 1.04
CD95 (APO-1/Fas)-associating signalling proteins. Cell Death Differ (1996) 1.02
Positive therapeutic and neurotropic effects of yoga in depression: A comparative study. Indian J Psychiatry (2013) 1.00
Effect of yoga therapy on plasma oxytocin and facial emotion recognition deficits in patients of schizophrenia. Indian J Psychiatry (2013) 0.97
Cortisol and antidepressant effects of yoga. Indian J Psychiatry (2013) 0.93
A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene (2012) 0.92
Randomized clinical trial of yoga-based intervention in residents from elderly homes: Effects on cognitive function. Indian J Psychiatry (2013) 0.91
Designing, validation and feasibility of a yoga-based intervention for elderly. Indian J Psychiatry (2013) 0.90
Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology (2005) 0.90
Integrating yoga in mental health services. Indian J Med Res (2015) 0.90
Development and feasibility of yoga therapy module for out-patients with depression in India. Indian J Psychiatry (2013) 0.87
Yoga increases the volume of the hippocampus in elderly subjects. Indian J Psychiatry (2013) 0.87
Efficacy of yoga as an add-on treatment for in-patients with functional psychotic disorder. Indian J Psychiatry (2013) 0.85
Feasibility and efficacy of yoga as an add-on intervention in attention deficit-hyperactivity disorder: An exploratory study. Indian J Psychiatry (2013) 0.85
Effects of yoga intervention on sleep and quality-of-life in elderly: A randomized controlled trial. Indian J Psychiatry (2013) 0.84
The death inhibitory molecules CED-9 and CED-4L use a common mechanism to inhibit the CED-3 death protease. J Biol Chem (1998) 0.84
Positive antidepressant effects of generic yoga in depressive out-patients: A comparative study. Indian J Psychiatry (2013) 0.83
Yoga and epilepsy: What do patients perceive? Indian J Psychiatry (2013) 0.79
Effect of yoga therapy on anxiety and depressive symptoms and quality-of-life among caregivers of in-patients with neurological disorders at a tertiary care center in India: A randomized controlled trial. Indian J Psychiatry (2013) 0.78
[Developing a molecular marker profile for prognosis of the course of benign prostatic hyperplasia]. Urologe A (2007) 0.75
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol (2016) 0.75
Effect of Mobile Phone-Induced Electromagnetic Field on Brain Hemodynamics and Human Stem Cell Functioning: Possible Mechanistic Link to Cancer Risk and Early Diagnostic Value of Electronphotonic Imaging. J Stem Cells (2015) 0.75
Keystone 1997: return of the worm. Temarron, Colorado, February 18-23, 1997. Cell Death Differ (1997) 0.75